GeoVax (United States)

GeoVax (United States)

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for GeoVax (United States), United States, covering academic research published from 2007 to 2024. Read More.


Open Access Percentage

80%


Total
Publications

54


Total Open
Publications

43


Total
Citations

1.2K


Open Access
Percentage

80%


Total
Publications

54


Total Open
Publications

43


Total
Citations

1.2K

Wikipedia

Website

download

Breakdown

6% 62% 11% 21%

Publisher Open

6%

Both

62%

Other Platform Open

11%

Closed

21%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

012345678Total Publications
200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

64%OA Journal

OA Journal 64%

23

Hybrid 8%

3

No Guarantees 28%

10

Other Platform Open

Domain 87%

34

Other Internet 15%

6

Institution 8%

3

Public 8%

3

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
34
DOI
Other Internet
6
Figshare
Public
3
Europe PMC
Domain
3
Université de Lausanne - SERVAL
Institution
1
JAMA - The Journal of the American Medical Association Network
Institution
1
DASH - Digital Access to Scholarship at Harvard
Institution
1
1 / 1

Data updated 18 August 2025

Share

Share

Share